# Original Article Association analysis of GWAS hits and non-syndromic cleft lip with/without palate with cleft alveolar in Han population of western China

Shijun Duan<sup>1\*</sup>, Jiayu Shi<sup>2\*</sup>, Bing Shi<sup>1</sup>, Zhonglin Jia<sup>1</sup>

<sup>1</sup>State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Cleft Lip and Palate Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China; <sup>2</sup>Department of Orthodontics and Pediatric Dentistry, School of Dentistry, The University of Michigan, Ann Arbor, Mich, USA. \*Equal contributors.

Received June 10, 2020; Accepted September 3, 2020; Epub October 1, 2020; Published October 15, 2020

**Abstract:** Cleft alveolar is often accompanied by non-syndromic cleft lip with/without palate (NSCL/P), which could seriously affect the growth and development of the maxilla. In this study, we assessed the associations between 47 susceptible SNPs from previous GWASs of NSCL/P and cleft alveolar in Western Han Chinese population. We recruited 228 trios of NSCL/P with cleft alveolar (156 males and 72 females). The 47 SNPs were genotyped by SNPscan method; Hardy-Weinberg equilibrium test, TDT and parent-of-origin effects were analyzed by PLINK; linkage disequilibrium analysis was conducted by Haploview software. TDT analysis revealed *FOXE1* rs894673 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) and rs3758249 (P = 0.0071, OR<sub>transmission</sub> = 0.039) of *FOXE1*. Allele A at rs894673 (P = 0.039), allele T at rs3759249 (P = 0.039), and allele T at rs4460498 (P = 0.039) of *FOXE1*. Allele A at rs987525 showed a significant paternal over-transmission (P = 0.0077). Pairwise LD analysis showed strong LD among rs894673, rs3759249 and rs4460498 ( $r^2 > 0.95$ , D' = 1). To conclude, our findings indicated that *FOXE1* is the susceptible gene for cleft alveolar accompanied by NSCL/P.

Keywords: Cleft alveolar, non-syndromic cleft lip with/without palate, susceptible gene, association study

#### Introduction

Non-syndromic cleft lip with or without cleft palate (NSCL/P), as common congenital birth defects, comprise a range of morphological abnormalities of oral and maxillofacial regions. Based on previous epidemiologic studies, Chinese have higher incidences of NSCL/P compared to other ethnicities [1-3], and the prevalence of NSCL/P was more than 1.6% in China [4, 5]. In particular, the incidence rate of NS-CL/P in western regions was significantly higher than that of other regions of China [5].

Cleft alveolus is a severe bony defect malformation that is present in 75% of NSCL/P [6]. The cleft alveolar refers to a space in the alveolar bone of maxilla with a discontinuity of the dental arch. This bony defect of the alveolus can prevent normal eruption of the cleft-adjacent permanent teeth, disrupt the stability of the maxillary segments, and maintain an oronasal fistula [6-8]. Each of these problems requires a special rehabilitation to avoid malocclusion, maxillary constriction or face asymmetry. Despite the mature sequential therapy involving alveolar bone grafting, the patients had maxillary growth retardation and craniofacial abnormalities thereafter [9].

Achieving a successful and well-functioning reconstruction is the ideal goal of cleft alveolar repair. Alveolar bone grafting is generally considered a gold standard for alveolar cleft treatment. However, the failure rate of this procedure was up to 15%, and normally accompanied with a serious of complications including pain, bleeding, infection, fracture, scar, or chronic pain [8-10]. Bearing in mind all the abovementioned implications accompanying cleft alveolus repair, the pathogenesis of this deformity is worthwhile to explore.

Genome-wide association study (GWAS) has obvious advantages in the etiology of genetic diseases, and is widely used to unravel the genetic basis of complex diseases [11-13]. Previous GWASs had revealed many susceptibility genes/loci for NSCL/P, which had provided more clues for detecting the etiology of clefts [14-19]. Until now, only 20% of the heritability could be explained. NSCL/P is still an important birth defect affecting quality of the birth in China. Etiological research is crucial to the prevention and control of this disease.

The premaxilla and upper lip come from the maxillary processes and medial nasal process. Cleft alveolus, as a common phenotype of bone malformation, is often accompanied by NSCL/P. Previous GWASs referring to NSCL/P identified susceptible genes of cleft lip. Unfortunately, there are no published data regarding the genetic background of cleft alveolus. In this study, we conducted an experiment with caseparent trios design to validate the association between 47 single nucleotide polymorphisms (SNPs) and cleft alveolus. The purpose of this study was to identify the susceptible genes related to cleft alveolar.

### Materials and methods

## Ethics statement

All the participants signed the informed consent before being recruited in this study. For patients younger than 16 years old, the informed consents were written by their guardians. The study protocols were reviewed and approved by the Hospital Ethics Committee (HEC) of West China Hospital of Stomatology (No. 2010080), Sichuan University.

## Samples description

We recruited 228 case-parent trios of NSCL/P with cleft alveolar, including 156 males and 72 females of the probands, who hospitalized between 2008 and 2013 in the Cleft Lip and Palate Surgery Department of West China Stomatology College, Sichuan University. The probands with non-syndromic cleft lip with or without cleft palate accompanied with cleft alveo-

lus and their parents were enrolled in this study. All the patients were checked by at least 2 professional maxillofacial doctors of the West China Hospital of Stomatology. The probands with other congenital deformities or mental retardation were excluded. All participants were restricted as Western Han Chinese according to self-identification.

### SNPs selection and genotyping

Based on the previous GWAS findings about NSCL/P, we selected 47 SNPs with the most significant P values in published studies. Primary information of these SNPs is shown in **Table 1**.

Venous blood samples were collected from all participants after recruitment in the study. Genomic DNA was extracted using the protein precipitation method [20]. All the experiments of genotyping were done by the Genesky Biopharm Technology Company (http://www.geneskies.com/) with SNPscan technology.

### Statistical analysis

The Hardy-Weinberg Equilibrium (HWE) analysis and the minor allele of frequency (MAF) determination were performed to check the deviation for each SNP among the unaffected parents. The HWE analysis was calculated through chi-square test. The MAF and allelic transmission disequilibrium test (TDT) and parent-of-origin effects analyses were calculated by PLINK software (http://zzz.bwh.harvard. edu/plink/data.shtml) [21]. The TDT analysis is a family-based association analysis method, which accessed whether the probability of two different alleles passed from heterozygous parents to their affected offspring varies by 50%. Pairwise linkage disequilibrium (LD) was calculated as D' and r<sup>2</sup> for 10 SNPs of 3 target genes (including NTN1, FOXE1 and VAX1) to identify LD blocks by the Haploview online software (http://www.broad.mit.edu/mpg/haploview/ index.php). Linkage analysis is based on the principle of meiosis chromosomal exchange and recombination. To determine the correlation between genetic markers and the disease. the separation of genetic markers in a family was observed to see whether these markers were tightly linked with each other.

Table 1. Primary information on 47 SNPs

Chr	SNP	Position (Hg19)	Gene	Function
1	rs4920522	18940380	PAX7	intergenic
1	rs766325	18956458	PAX7	intergenic
1	rs6695765	18979320	PAX7	intron
1	rs742071	18979874	PAX7	intron
1	rs560426	94553438	ABCA4	intron
1	rs481931	94570016	ABCA4	intron
1	rs4147811	94575056	ABCA4	intron
1	rs6677101	108699730	SLC25A24	intron
1	rs2235371	209964080	IRF6	extron
1	rs642961	209989270	IRF6	intergenic
1	rs126280	210019824	DIEXF	intron
1	rs2064163	210048819	DIEXF	intergenic
1	rs12063989	210049893	DIEXF	intergenic
1	rs4844913	210068117	SYT14	intergenic
1	rs9429830	210110537	SYT14	intergenic
1	rs11119388	210174417	SYT14	intron
1	rs227178	210216946	SYT14	intron
1	rs2485893	210348155	SYT14	intergenic
2	rs7590268	43540125	THADA	intron
3	rs7632427	89534377	EPHA3	intergenic
4	rs12506428	93830884	GRID2	intron
8	rs6558002	27389542	EPHX2	intron
8	rs12543318	88868340	DCAF4L2	intergenic
8	rs987525	129946154	LOC728724	intergenic
9	rs894673	100612270	FOXE1	intergenic
9	rs3758249	100614140	FOXE1	intergenic
9	rs4460498	100620412	FOXE1	intergenic
10	rs7078160	118827560	VAX1	intron
10	rs4752028	118834991	VAX1	intron
13	rs9574565	80668874	SPYR2	intergenic
13	rs8001641	80692811	SPYR2	intergenic
14	rs17563	54417522	BMP4	exon
15	rs1258763	33050423	FMN1	intergenic
15	rs7179658	63312695	TPM1	intergenic
16	rs8049367	3980445	CREBBP-ADCY9	intergenic
17	rs9788972	8919630	NTN1	intergenic
17	rs4791774	8932119	NTN1	intron
17	rs9915089	8952894	NTN1	intron
17	rs8069536	8956285	NTN1	intron
17	rs8081823	8965551	NTN1	intron
17	rs17760296	54615617	NOG	intergenic
20	rs6072081	39261054	MAFB	intergenic
20	rs6065259	39261979	MAFB	intergenic
20	rs17820943	39268516	MAFB	intergenic
20	rs13041247	39269074	MAFB	intergenic
20	rs11698025	39274083	MAFB	intergenic
20	rs6102085	39281629	MAFB	intergenic

Note: Chr, chromosome; SNP, single-nucleotide polymorphism.

### Results

Except for rs481931 and rs4147811, the genotypic distribution of remaining SNPs did not deviate from the Hardy-Weinberg equilibrium (P > 0.01) (**Table 2**).

Allelic TDT analysis was usually assessed the transmission of minor alleles from heterozygous informative parents to affected child within case-parents trios. The results showed allele A at rs894673 of FOXE1 (P = 0.0071,  $OR_{transmission} = 0.35, 95\% CI: 0.16-0.78),$ and allele T at rs3758249 of FOXE1 (P = 0.0071, OR<sub>transmission</sub> = 0.35, 95% CI: 0.16-0.78) were under-transmitted. Allele A at rs7078160 and allele C at rs4752028 of VAX1 showed a tendency of over-transmission (P = 0.039, OR<sub>transmission</sub> = 1.62, 95% CI: 1.02-2.58;  $P = 0.024, \text{ OR}_{\text{transmission}} = 1.73, 95\%$  CI: 1.07-2.81; respectively) (Table 3).

In parent-of-origin effects analysis, allele A at rs894673, allele T at rs37-58249 and allele T at rs4460498 of *FOXE1* showed a weak paternal special under-transmission bias (P = 0.039; P = 0.039; P = 0.039; respectively). Allele A at rs987525 (downstream of *LO*-*C728724*) showed a relatively strong paternal special over-transmission bias (P = 0.0077) (**Table 4**). However, no significant difference was found within combined analysis between father and mother.

We calculated the pairwise LD of SNPs on 3 target genes (including *NTN1*, *FOXE1* and *VAX1*) based the association results. Pairwise LD analysis indicated that the SNPs of *FOXE1* (rs89-4673, rs3758249, and rs4460498) were significantly linked with each other ( $r^2 > 0.95$ , D' = 1) (**Figure 1**).

#### Discussion

Phenotype is an observable or measurable trait of a disease. Some typical phenotype (e.g. lower lip pits for Van der Woude syndrome; bilateral zygomatic and malar hypoplasia for Treacher Collins syndrome) is impor-

				0-1	LI\\/E		
SNP	A1	A2	MAF	GENO	O (HET)	E (HET)	P
rs4920522	Т	С	23.61%	14/76/137	0.33	0.35	0.45
rs766325	А	G	21.13%	8/75/144	0.33	0.32	0.84
rs6695765	С	Т	37.17%	30/95/100	0.42	0.45	0.38
rs742071	Т	G	5.20%	0/16/211	0.070	0.068	1
rs560426	C	T	32.85%	17/111/99	0.49	0.43	0.068
rs481931	T	G	32.55%	11/115/99	0.51	0.42	0.0025
rs4147811	т	c	33.19%	11/117/99	0.52	0.42	0.0016
rs6677101	т	G	46.20%	51/111/64	0.49	0.50	0.89
rs2235371	т	C C	33.41%	31/97/99	0.43	0.46	0.38
rs642961	Α.	G	24.23%	13/82/132	0.36	0.36	1
rs126280	Δ	G	23.81%	11/79/134	0.35	0.35	- 1
rs2064163	т	G	39 73%	37/107/82	0.47	0.48	0.89
rs12063989	Ċ	T	36.38%	35/100/91	0.44	0.47	0.40
rs4844013	G	Δ	47.22%	46/106/74	0.47	0.49	0.50
rs9129830	т	0	49 76%	63/87/58	0.42	0.40	0.00
rs11110222	C I	Δ	40.71%	<u>11/90/81</u>	0.42	0.30	0.013
rs227178	c c	T	40.71/0	39/92/20	0.44	0.40	0.13
rs2/25202	C C	Δ	47 25%	45/103/79	0.45	0.40	0.21
rs7590268	G	T	3 4 1%	0/15/010	0.43	0.45	1
rs7639/197	G C	т Т	16 / 2%	0/ 10/ 212 A/70/152	0.07	0.004	1 0 25
rs1052421	C C	י ד	10.40%	60/106/61	0.31	0.20	0.25
1312300420	C C	т Т	16 10%	5/59/16/01	0.47	0.50	1
rs105/2210	~	r C	24 40%	28/105/04	0.20	0.25	1
1312043318	A _	C	34.4U%	20/100/94	0.40	0.40	0 30 T
13301323	A _	с т	0.J∠%	2/20/13/	0.12	0.13	0.30
13034013	A T		12.12%	3/49/1/4 2/50/474	0.22	0.21	1
153138249	 -	C	10.00%	3/50/1/4	0.22	0.22	1
154460498	1	C	12.83%	3/49/1/4	0.22	0.21	1
15/0/8160	A	G	49.11%	57/115/55	0.51	0.50	0.89
154/52028	C -		38.94%	38/112///	0.49	0.49	0.89
rs9574565	1	C	12.72%	6/44/1//	0.19	0.22	0.12
rs8001641	A	G	14.67%	2/67/156	0.30	0.27	0.082
rs1/563	G _	A	31.25%	23/94/109	0.42	0.43	0.76
rs1258/63	T	С —	8.33%	2/38/186	0.17	0.17	1
rs/1/9658	С _	ſ	15.82%	5/60/162	0.26	0.26	1
rs8049367	T	C	34.29%	35/96/96	0.42	0.46	0.20
rs9/88972	A	G	22.57%	14/68/145	0.30	0.33	0.16
rs4/91/74	G _	A	22.62%	11//3/143	0.32	0.33	0.69
rs9915089	Т	С	19.47%	8/67/152	0.30	0.30	0.83
rs8069536	Т	G	3.65%	0/13/214	0.057	0.06	1
rs8081823	A	G	39.89%	31/112/83	0.50	0.47	0.57
rs17760296	G	Т	1.55%	0/8/219	0.035	0.035	1
rs6072081	G	A	39.05%	31/116/80	0.51	0.48	0.33
rs6065259	А	G	36.76%	29/107/86	0.48	0.47	0.67
rs17820943	Т	С	39.38%	31/116/80	0.51	0.48	0.33
rs13041247	С	Т	39.38%	31/116/80	0.51	0.48	0.33
rs11698025	А	G	32.15%	21/99/107	0.44	0.43	0.88

Table 2. Minor Allele Frequency and Hardy-Weinberg Equilibrium test for 47 SNPs

rs6102085	А	G	42.86%	42/115/69	0.51	0.49	0.69		
Note: SNP, single-nucleotide polymorphism; A1, minor allele; A2, major allele; MAF, minor allele frequency; HWE, Hardy-Wein-									

berg Equilibrium test; GENO, genotype; O (HET), observed heterozygosity; E (HET), expect heterozygosity.

Table 3. Allelic transmission	disequilibrium te	est results	for 47	SNPs
-------------------------------	-------------------	-------------	--------	------

	A1 T-11	<b>T</b> .L.I		Р			Parental	COM		
5NP	AL	1:0	CHISQ	Р	UR (95% CI)	A:U	CHISQ	Р	CHISQ	Р
rs4920522	Т	26:23	0.18	0.67	1.13 (0.65-1.98)	69:60	0.46	0.50	0.64	0.42
rs766325	А	24:23	0.02	0.88	1.04 (0.59-1.85)	67:55	0.92	0.34	0.83	0.36
rs6695765	С	34:29	0.40	0.53	1.17 (0.71-1.92)	94:62	5.02	0.025	5.13	0.024
rs742071	Т	10:5	1.67	0.20	2.00 (0.68-5.85)	31:16	4.41	0.036	6.06	0.014
rs560426	С	42:28	2.80	0.094	1.50 (0.93-2.42)	74:63	0.74	0.39	2.68	0.10
rs481931	Т	31:39	0.91	0.34	0.79 (0.50-1.27)	80:60	2.27	0.13	0.59	0.44
rs4147811	Т	35:41	0.47	0.49	0.85 (0.54-1.34)	83:58	3.57	0.059	1.44	0.23
rs6677101	Т	42:30	2.00	0.16	1.40 (0.88-2.24)	74:81	0.24	0.63	0.090	0.77
rs2235371	Т	39:38	0.013	0.91	1.03 (0.66-1.60)	70:81	0.62	0.43	0.37	0.54
rs642961	А	23:26	0.18	0.67	0.88 (0.50-1.55)	66:62	0.10	0.75	0.0049	0.94
rs126280	А	20:28	1.33	0.25	0.71 (0.40-1.27)	70:55	1.53	0.22	0.25	0.62
rs2064163	Т	32:37	0.36	0.55	0.86 (0.54-1.39)	82:80	0.019	0.89	0.032	0.86
rs12063989	С	31:38	0.71	0.40	0.82 (0.51-1.31)	73:80	0.25	0.62	0.73	0.39
rs4844913	G	40:33	0.67	0.41	1.21 (0.76-1.92)	100:70	4.05	0.044	4.64	0.031
rs9429830	Т	30:25	0.45	0.50	1.20 (0.71-2.04)	67:78	0.61	0.44	0.14	0.71
rs11119388	G	38:40	0.051	0.82	0.95 (0.61-1.48)	80:86	0.16	0.69	0.22	0.64
rs227178	С	36:32	0.24	0.63	1.13 (0.70-1.81)	105:67	6.28	0.012	5.92	0.015
rs2485893	G	39:32	0.69	0.41	1.22 (0.76-1.95)	108:62	9.36	0.0022	9.46	0.0021
rs7590268	G	1:8	5.44	0.020	0.13 (0.016-1.00)	14:12	0.15	0.70	0.71	0.40
rs7632427	С	14:18	0.50	0.48	0.78 (0.39-1.56)	46:58	1.16	0.28	1.64	0.20
rs12506428	С	32:41	1.11	0.29	0.78 (0.49-1.24)	78:83	0.11	0.74	0.66	0.42
rs6558002	С	10:20	3.33	0.068	0.50 (0.23-1.07)	50:42	0.60	0.44	0.029	0.86
rs12543318	А	30:37	0.73	0.39	0.81 (0.50-1.31)	70:77	0.24	0.62	0.73	0.39
rs987525	А	15:7	2.91	0.088	2.14 (0.87-5.26)	41:28	2.25	0.13	4.55	0.033
rs894673	А	8:23	7.26	0.0071	0.35 (0.16-0.78)	38:37	0.012	0.91	1.75	0.19
rs3758249	Т	8:23	7.26	0.0071	0.35 (0.16-0.78)	39:38	0.012	0.91	1.72	0.19
rs4460498	Т	8:22	6.53	0.011	0.36 (0.16-0.82)	37:37	0	1.00	1.78	0.18
rs7078160	А	47:29	4.26	0.039	1.62 (1.02-2.58)	69:77	0.35	0.56	0.38	0.54
rs4752028	С	45:26	5.09	0.024	1.73 (1.07-2.81)	67:82	1.19	0.28	0.062	0.80
rs9574565	Т	16:14	0.13	0.72	1.14 (0.56-2.34)	47:42	0.25	0.62	0.37	0.54
rs8001641	А	18:14	0.50	0.48	1.29 (0.64-2.59)	43:53	0.93	0.34	0.26	0.61
rs17563	G	28:29	0.018	0.89	0.97 (0.57-1.62)	73:74	0.0056	0.94	0.017	0.90
rs1258763	Т	8:8	0	1.00	1.00 (0.38-2.67)	29:38	1.08	0.30	0.89	0.35
rs7179658	С	23:17	0.90	0.34	1.35 (0.72-2.53)	57:54	0.074	0.79	0.50	0.48
rs8049367	Т	33:24	1.42	0.23	1.38 (0.81-2.33)	69:89	1.96	0.16	0.46	0.50
rs9788972	А	19:30	2.47	0.12	0.63 (0.36-1.13)	72:60	0.91	0.34	0.0048	0.94
rs4791774	G	21:26	0.53	0.47	0.81 (0.45-1.44)	69:55	1.34	0.25	0.42	0.52
rs9915089	Т	16:30	4.26	0.039	0.53 (0.29-0.98)	68:56	0.94	0.33	0.020	0.89
rs8069536	т	4:7	0.82	0.37	0.57 (0.17-1.95)	20:13	1.49	0.22	0.36	0.55
rs8081823	А	36:37	0.014	0.91	0.97 (0.62-1.54)	96:84	0.61	0.44	0.39	0.53
rs17760296	G	2:2	0	1.00	1.00 (0.14-7.10)	6:8	0.29	0.59	0.22	0.64
rs6072081	G	35:46	1.49	0.22	0.76 (0.49-1.18)	75:73	0.021	0.88	0.30	0.58

rs6065259	А	32:42	1.35	0.25	0.76 (0.48-1.21)	73:73	0	1.00	0.38	0.54
rs17820943	Т	36:46	1.22	0.27	0.78 (0.51-1.21)	74:71	0.048	0.83	0.18	0.67
rs13041247	С	36:46	1.22	0.27	0.78 (0.51-1.21)	74:71	0.048	0.83	0.18	0.67
rs11698025	А	35:41	0.47	0.49	0.85 (0.54-1.34)	71:60	0.74	0.39	0.10	0.75
rs6102085	А	36:38	0.054	0.82	0.95 (0.60-1.49)	79:82	0.043	0.84	0.088	0.77

Note: SNP, single-nucleotide polymorphism; A1, minor allele; T:U, transmitted:untransmitted; OR, odds ratio; A:U, discordance counts; COM, combined analysis results; Bold characters indicate the items with *P*-value less than 0.05.

	A1:A2	Paternal		Maternal			7		
SNF		T:U	CHISQ	Р	T:U	CHISQ	Р	Z	Ρ
rs4920522	T:C	15:11	0.62	0.43	11:12	0.043	0.83	0.69	0.49
rs766325	A:G	12.5:12.5	0	1	11.5:10.5	0.045	0.83	-0.16	0.88
rs6695765	C:T	15.5:12.5	0.32	0.57	18.5:16.5	0.11	0.74	0.20	0.84
rs742071	T:G	2:3	0.20	0.65	8:2	3.60	0.058	-1.48	0.14
rs560426	C:T	17:14	0.29	0.59	25:14	3.10	0.078	-0.78	0.43
rs481931	T:G	17:26	1.88	0.17	14:13	0.037	0.85	-1.01	0.31
rs4147811	T:C	19.5:24.5	0.57	0.45	15.5:16.5	0.031	0.86	-0.36	0.72
rs6677101	T:G	20:18	0.11	0.75	22:12	2.94	0.086	-1.03	0.30
rs2235371	T:C	19:20	0.026	0.87	20:18	0.11	0.75	-0.34	0.73
rs642961	A:G	9.5:13.5	0.70	0.40	13.5:12.5	0.038	0.84	-0.74	0.46
rs126280	A:G	8:12	0.80	0.37	12:16	0.57	0.45	-0.20	0.84
rs2064163	T:G	15:21	1	0.32	17:16	0.030	0.86	-0.82	0.41
rs12063989	C:T	15.5:20.5	0.69	0.40	15.5:17.5	0.12	0.73	-0.33	0.74
rs4844913	G:A	21.5:14.5	1.36	0.24	18.5:18.5	0	1	0.83	0.40
rs9429830	T:C	13.5:13.5	0	1	16.5:11.5	0.89	0.34	-0.66	0.51
rs11119388	G:A	18.5:18.5	0	1	19.5:21.5	0.098	0.75	0.22	0.83
rs227178	C:T	19.5:14.5	0.74	0.39	16.5:17.5	0.029	0.86	0.73	0.47
rs2485893	G:A	22:13	2.31	0.13	17:19	0.11	0.74	1.32	0.19
rs7590268	G:T	1:4	1.80	0.18	0:4	4	0.046	NA	NA
rs7632427	C:T	7:12	1.32	0.25	7:6	0.077	0.78	-0.95	0.34
rs12506428	C:T	14.5:21.5	1.36	0.24	17.5:19.5	0.11	0.74	-0.60	0.55
rs6558002	C:T	5:12	2.88	0.09	5:8	0.69	0.41	-0.52	0.60
rs12543318	A:C	17:19	0.11	0.74	13:18	0.81	0.37	0.43	0.66
rs987525	A:C	8.5:0.5	7.11	0.0077	6.5:6.5	0	1	1.82	0.069
rs894673	A:T	3.5:11.5	4.27	0.039	4.5:11.5	3.06	0.080	-0.30	0.76
rs3758249	T:C	3.5:11.5	4.27	0.039	4.5:11.5	3.06	0.080	-0.30	0.76
rs4460498	T:C	3.5:11.5	4.27	0.039	4.5:10.5	2.4	0.12	-0.41	0.68
rs7078160	A:G	24.5:13.5	3.18	0.074	22.5:15.5	1.29	0.26	0.47	0.64
rs4752028	C:T	18.5:13.5	0.78	0.38	26.5:12.5	5.03	0.025	-0.88	0.38
rs9574565	T:C	7:10	0.53	0.47	9:4	1.92	0.17	-1.50	0.13
rs8001641	A:G	11.5:5.5	2.12	0.15	6.5:8.5	0.27	0.61	1.37	0.17
rs17563	G:A	10.5:12.5	0.17	0.68	17.5:16.5	0.029	0.86	-0.43	0.67
rs1258763	T:C	3:4	0.14	0.71	5:4	0.11	0.74	-0.50	0.62
rs7179658	C:T	13.5:9.5	0.70	0.40	9.5:7.5	0.24	0.63	0.18	0.86
rs8049367	T:C	17.5:11.5	1.24	0.27	15.5:12.5	0.32	0.57	0.38	0.70
rs9788972	A:G	9:13	0.73	0.39	10:17	1.82	0.18	0.28	0.78
rs4791774	G:A	10:13	0.39	0.53	11:13	0.17	0.68	-0.16	0.87
rs9915089	T:C	7:16	3.52	0.061	9:14	1.09	0.30	-0.62	0.54

Table 4. Parent-of-Origin effects analysis for 47 SNPs

rs8069536	T:G	0:3	3	0.083	4:4	0	1	NA	NA
rs8081823	A:G	19.5:23.5	0.37	0.54	16.5:13.5	0.30	0.58	-0.81	0.42
rs17760296	G:T	1:1	0	1	1:1	0	1	0	1
rs6072081	G:A	21.5:25.5	0.34	0.56	13.5:20.5	1.44	0.23	0.54	0.59
rs6065259	A:G	17:25	1.52	0.22	15:17	0.13	0.72	-0.55	0.58
rs17820943	T:C	20:24	0.36	0.55	16:22	0.95	0.33	0.30	0.76
rs13041247	C:T	20:24	0.36	0.55	16:22	0.95	0.33	0.30	0.76
rs11698025	A:G	16.5:22.5	0.92	0.34	18.5:18.5	0	1	-0.67	0.50
rs6102085	A:G	20.5:18.5	0.10	0.75	15.5:19.5	0.46	0.50	0.71	0.48

Note: SNP, single-nucleotide polymorphism; A1, minor allele; A2, major allele; T:U, transmitted:undertransmitted; Z, vector of the large sample Z statistic; NA, not available; Bold characters indicate the items with *P*-value less than 0.05.



Figure 1. Pairwise LD analysis of the target genes (NTN1, FOXE1 and VAX1) for cleft alveolus (A, D'; B, r<sup>2</sup>).

tant and usually will lead to a clinical diagnosis, which could provide information to infer the candidate genes with phenotypic similarities and consult the phenotype-genotype heterogeneous network [22, 23]. Previous genetic studies of NSCL/P paid more attention to NSCLO, NSCPO and NSCLP, and even combined analysis with mixed samples. As a specific phenotype, cleft alveolus has not been studied by itself.

The maxillary processes fuse with the medial nasal process to form the upper lip, alveolus, and primary palate during the 5th and 6th weeks of embryonic development [1, 24]. The process of forming alveolar bone has extensive similarity to the process in the upper lip, which arises from the same embryonic origin. Thus, we infer that cleft alveolus might share the same gene regulatory network with cleft lip.

*FOXE1*, located on 9q22, was initially suggested as a candidate gene through genome scanning and linkage analysis in some multiplex CL/P families [25]. Subsequently, significant SNPs that linked 9q22 region were replicated

in CL/P families of Colombia, USA, and the Philippines. Rs3758249 and rs4460498 showed highly significant signals, which were located inside a 70 kb high linkage disequilibrium block containing FOXE1. Then, expression of foxe1 was detected in caudal epithelium of medial nasal and maxillary processes at E11.5. Especially, foxe1 is obviously expressed in the stage of fusion between the medial nasal and maxillary processes [26]. Animal experiments had demonstrated that FOXE1 in knockout mice will lead to developmental malformation, including thyroid dysgenesis and cleft palate [27]. Then, FOXE1 overexpression experiments in a mouse model also displayed a phenotype of cleft palate, and FOXE1 was highly expressed in the medial edge epithelium (MEE) [28]. This evidence suggested that FOXE1 might regulate the pathogenesis of cleft lip and palate.

Notably, the impact of *FOXE1* on the NSCL/P should be validated in different ethnic groups in order to exclude the limitation of single populations' or regions' mutation. In a follow-up association study of fifty SNPs at 9q22, rs89-4673 and rs3758249 near *FOXE1* were geno-

typed in 291 multiplex cleft families. However, no significant association of FOXE1 was found in the test populations [29]. Subsequently, the association of target SNPs (rs894673, rs37-58249 and rs4460498) near FOXE1 with NS-CL/P were validated among distinct populations [30-33]. These results supported that FO-XE1 gene was a positive risk factor for orofacial cleft. In our study, rs894673 and rs3758249 showed a significant association with cleft alveolus, and rs4460498 showed a moderate association with cleft alveolus (Table 3). Meanwhile, marked parent of origin effects were seen with rs894673, rs3758249, and rs44-60498 alleles. Under-transmission was shown preferentially from comparing fathers to mothers (Table 4). Pair-wise LD analysis also showed a strong LD between rs894673, rs375-8249 and rs4460498 (Figure 1), indicating they were tightly linked with each other. All these findings suggested the pathogenesis of cleft alveolus involved FOXE1 gene expression and regulation.

Rs894673 and rs3758249 are located in the 5'-upstream region of FOXE1, speculating they might affect FOXE1 transcription by altering transcription factor binding sites. The entire promoter region of FOXE1 was screened with 35 cleft palate patients and 160 unaffected people to identify the suspicious variants A novel non-coding variant in the 5'-untranslated region of FOXE1 was found. Based on later cell experiments, the variant could prevent the binding of *MYF-5* to *FOXE1* promoter and affect the FOXE1 expression [34]. Rs4460498, located in the 3'-downstream region of FOXE1, was first reported to have an association with NS-CL/P among Caucasian and Asian populations with P value 6.51E-12 [26]. Three potentially functional SNPs of FOXE1 (two in the 5'-upstream and one in 3'-UTR) were replicated among central Chinese population in a following study. They found that the target SNP in 3'-UTR contributed to altering binding ability with target miRNA in in vitro studies [35].

Numerous studies had reported a significant association between rs987525 and NSCL/P in more than one population origin [14, 15, 18]. In this study, we found rs987525 had a mild association with parents and cases in combined TDT analysis (**Table 3**). But the association did

not present in the cases. Meanwhile, an allele of rs987525 showed a significant over-transmission from fathers compared to mothers (**Table 4**). Rs987525 located in 8q24, which had been demonstrated this region containing a remote *Myc*-regulated enhancer. Deletion of this region would lead to alternation of facial morphology, and even to CL/P phenotype [36]. Myc expression also can be regulated by such *cis*-enhancer element interacting with the Myc promoter by transcription factor Tcf-4 binding [37].

Rs481931 and rs4147811 deviated from the Hardy-Weinberg equilibrium (P < 0.01) in our samples, indicating it may need larger sample size to validate its significance. Previously, we had validated the association between these two SNPs and NSCL/P among 440 orofacial cleft trios. Unfortunately, rs481931 and rs41-47811 were not compatible with the Hardy-Weinberg equilibrium as well [38]. Maybe there was a higher genetic load from parents to the probands in the case-parents design of the research.

In summary, we replicated 47 SNPs contributing to NSCL/P to investigate their roles in cleft alveolus in a western Han Chinese population. Based on the current study, we confirmed *FOXE1* as a susceptible gene for the cleft alveolus, which provides a new research direction for the development of alveolar bone.

## Acknowledgements

We are particularly thankful to patients and their families who participated in this study. This work was supported by the National Science Funds of China (No. 81600849) and Sichuan Province Science and Technology support program (2020YJ0211).

### Disclosure of conflict of interest

## None.

Address correspondence to: Dr. Zhonglin Jia, State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Cleft Lip and Palate Surgery, West China College of Stomatology, Sichuan University, No. 14, 3rd Section, Renmin Nan Road, Chengdu 610041, China. Tel: +86-028-85503560; E-mail: zhonglinjia@sina.com

### References

- Mossey PA, Little J, Munger RG, Dixon MJ and Shaw WC. Cleft lip and palate. Lancet 2009; 374: 1773-1785.
- [2] Dixon MJ, Marazita ML, Beaty TH and Murray JC. Cleft lip and palate: understanding genetic and environmental influences. Nat Rev Genet 2011; 12: 167-178.
- [3] Beaty TH, Marazita ML and Leslie EJ. Genetic factors influencing risk to orofacial clefts: today's challenges and tomorrow's opportunities. F1000Res 2016; 5: 2800.
- [4] Dai L, Zhu J, Mao M, Li Y, Deng Y, Wang Y, Liang J, Tang L, Wang H, Kilfoy BA, Zheng T and Zhang Y. Time trends in oral clefts in Chinese newborns: data from the Chinese National Birth Defects Monitoring Network. Birth Defects Res Part A 2010; 88: 41-47.
- [5] Fan D, Wu S, Liu L, Xia Q, Tian G, Wang W, Ye S, Wang L, Rao J, Yang X, Yu Z, Xin L, Li S, Duan Z, Zhang T, Wu S, Guo X and Liu Z. Prevalence of non-syndromic orofacial clefts: based on 15,094,978 Chinese perinatal infants. Oncotarget 2018; 9: 13981-13990.
- [6] Cho-Lee GY, García-Díez EM, Nunes RA, Martí-Pagès C, Sieira-Gil R and Rivera-Baró A. Review of secondary alveolar cleft repair. Ann Maxillofac Surg 2013; 3: 46-50.
- Santiago PE, Schuster LA and Levy-Bercowski
  D. Management of the alveolar cleft. Clin Plastic Surg 2014; 41: 219-232.
- [8] Fudalej P, Janiszewska-Olszowska J, Wedrychowska-Szulc B and Katsaros C. Early alveolar bone grafting has a negative effect on maxillary dental arch dimensions of pre-school children with complete unilateral cleft lip and palate. Orthod Craniofac Res 2011; 14: 51-57.
- [9] Gładysz D and Hozyasz KK. Stem cell regenerative therapy in alveolar cleft reconstruction. Arch Oral Biol 2015; 60: 1517-1532.
- [10] Stasiak M, Wojtaszek-Słomińska A and Racka-Pilszak B. Current methods for secondary alveolar bone grafting assessment in cleft lip and palate patients-A systematic review. J Craniomaxillofac Surg 2019; 47: 578-585.
- [11] Xu H and Shete S. Effects of population structure on genetic association studies. BMC Genet 2005; 6: S109.
- [12] Guo X and Rotter JI. Genome-wide association studies. JAMA 2019; 322: 1705-1706.
- [13] Mills MC and Rahal C. The GWAS diversity monitor tracks diversity by disease in real time. Nat Genet 2020; 52: 242-243.
- [14] Birnbaum S, Ludwig KU, Reutter H, Herms S, Steffens M, Rubini M, Baluardo C, Ferrian M, de Assis NA, Alblas MA, Barth S, Freudenberg J, Lauster C, Schmidt G, Scheer M, Braumann B, Berge SJ, Reich RH, Schiefke F, Hemprich A,

Pötzsch S, Steegers-Theunissen RP, Pötzsch B, Moebus S, Horsthemke B, Kramer FJ, Wienker TF, Mossey PA, Propping P, Cichon S, Hoffmann P, Knapp M, Nöthen MM and Mangold E. Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. Nat Genet 2009; 41: 473-477.

- [15] Grant SA, Wang K, Zhang H, Glaberson W, Annaiah K, Kim CE, Bradfield JP, Glessner JT, Thomas KA, Garris M, Frackelton EC, Otieno FG, Chiavacci RM, Nah HD, Kirschner RE and Hakonarson H. A genome-wide association study identifies a locus for nonsyndromic cleft lip with or without cleft palate on 8q24. J Pediatr 2009; 155: 909-913.
- [16] Beaty TH, Murray JC, Marazita ML, Munger RG, Ruczinski I, Hetmanski JB, Liang KY, Wu T, Murray T, Fallin MD, Redett RA, Raymond G, Schwender H, Jin SC, Cooper ME, Dunnwald M, Mansilla MA, Leslie E, Bullard S, Lidral AC, Moreno LM, Menezes R, Vieira AR, Petrin A, Wilcox AJ, Lie RT, Jabs EW, Wu-Chou YH, Chen PK, Wang H, Ye X, Huang S, Yeow V, Chong SS, Jee SH, Shi B, Christensen K, Melbye M, Doheny KF, Pugh EW, Ling H, Castilla EE, Czeizel AE, Ma L, Field LL, Brody L, Pangilinan F, Mills JL, Molloy AM, Kirke PN, Scott JM, Arcos-Burgos M and Scott AF. A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet 2010; 42: 525-529.
- [17] Sun Y, Huang Y, Yin A, Pan Y, Wang Y, Wang C, Du Y, Wang M, Lan F, Hu Z, Wang G, Jiang M, Ma J, Zhang X, Ma H, Ma J, Zhang W, Huang Q, Zhou Z, Ma L, Li Y, Jiang H, Xie L, Jiang Y, Shi B, Cheng J, Shen H, Wang L and Yang Y. Genomewide association study identifies a new susceptibility locus for cleft lip with or without a cleft palate. Nat Commun 2015; 6: 6414.
- [18] Yu Y, Zuo X, He M, Gao J, Fu Y, Qin C, Meng L, Wang W, Song Y, Cheng Y, Zhou F, Chen G, Zheng X, Wang X, Liang B, Zhu Z, Fu X, Sheng Y, Hao J, Liu Z, Yan H, Mangold E, Ruczinski I, Liu J, Marazita ML, Ludwig KU, Beaty TH, Zhang X, Sun L and Bian Z. Genome-wide analyses of non-syndromic cleft lip with palate identify 14 novel loci and genetic heterogeneity. Nat Commun 2017; 8: 14364.
- [19] Huang L, Jia Z, Shi Y, Du Q, Shi J, Wang Z, Mou Y, Wang Q, Zhang B, Wang Q, Ma S, Lin H, Duan S, Yin B, Lin Y, Wang Y, Jiang D, Hao F, Zhang L, Wang H, Jiang S, Xu H, Yang C, Li C, Li J, Shi B and Yang Z. Genetic factors define CPO and CLO subtypes of nonsyndromicorofacial cleft. PLoS Genet 2019; 15: e1008357.
- [20] Yu Q, He S, Zeng N, Ma J, Zhang B, Shi B and Jia Z. *BMP7* gene involved in nonsyndromic orofacial clefts in Western Han Chinese. Med Oral Patol Oral Cir Bucal 2015; 20: e298-304.

- [21] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MR, Bender D, Maller J, Sklar P, de Bakker PW, Daly MJ and Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
- [22] Zhang SH, Wu C, Li X, Chen X, Jiang W, Gong BS, Li J and Yan YQ. From phenotype to gene: detecting disease-specific gene functional modules via a text-based human disease phenotype network construction. FEBS Lett 2010; 584: 3635-3643.
- [23] Yao X, Hao H, Li Y and Li S. Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotypegene heterogeneous network. BMC Syst Biol 2011; 5: 79.
- [24] Seifeldin SA. Is alveolar cleft reconstruction still controversial? Saudi Dent J 2016; 28: 3-11.
- [25] Marazita ML, Murray JC, Lidral AC, Arcos-Burgos M, Cooper ME, Goldstein T, Maher BS, Daack-Hirsch S, Schultz R, Adela Mansilla M, Leigh Field L, Liu Y, Prescott N, Malcolm S, Winter R, Ray A, Moreno L, Valencia C, Neiswanger K, Wyszynski DF, Bailey-Wilson JE, Albacha-Hejazi H, Beaty TH, McIntosh I, Hetmanski JB, Tuncbilek G, Edwards M, Harkin L, Scott R and Roddick LG. Meta-analysis of 13 genome scans reveals multiple cleft lip/palate genes with novel loci on 9q21 and 2q32-35. Am J Hum Genet 2004; 75: 161-173.
- [26] Moreno LM, Mansilla MA, Bullard SA, Cooper ME, Busch TD, Machida J, Johnson MK, Brauer D, Krahn K, Daack-Hirsch S, L'Heureux J, Valencia-Ramirez C, Rivera D, Maria López A, Moreno MA, Hing A, Lammer EJ, Jones M, Christensen K, Lie RT, Jugessur A, Wilcox AJ, Chines P, Pugh E, Doheny K, Arcos-Burgos M, Marazita ML, Murray JC and Lidral AC. FOXE1 association with both isolated cleft lip with or without cleft palate, and isolated cleft palate. Hum Mol Genet 2009; 18: 4879-4896.
- [27] De Felice M, Ovitt C, Biffali E, Rodriguez-Mallon A, Arra C, Anastassiadis K, Macchia PE, Mattei MG, Mariano A, Schöler H, Macchia V and Di Lauro R. A mouse model for hereditary thyroid dysgenesis and cleft palate. Nat Genet 1998; 19: 395-398.
- [28] Meng T, Shi JY, Wu M, Wang Y, Li L, Liu Y, Zheng Q, Huang L and Shi B. Overexpression of mouse *TTF-2* gene causes cleft palate. J Cell Mol Med 2012; 16: 2362-2368.
- [29] Letra A, Menezes R, Govil M, Fonseca RF, McHenry T, Granjeiro JM, Castilla EE, Orioli IM, Marazita ML and Vieira AR. Follow-up association studies of chromosome region 9q and nonsyndromic cleft lip/palate. Am J Med Genet Part A 2010; 152A: 1701-1710.

- [30] Ludwig KU, Böhmer AC, Rubini M, Mossey PA, Herms S, Nowak S, Reutter H, Alblas MA, Lippke B, Barth S, Paredes-Zenteno M, Muñoz-Jimenez SG, Ortiz-Lopez R, Kreusch T, Hemprich A, Martini M, Braumann B, Jäger A, Pötzsch B, Molloy A, Peterlin B, Hoffmann P, Nöthen MM, Rojas-Martinez A, Knapp M, Steegers-Theunissen RP and Mangold E. Strong association of variants around *FOXE1* and orofacial clefting. J Dent Res 2004; 93: 376-381.
- [31] Liu K, Lu Y, Ai L, Jiao B, Yu J, Zhang B and Liu Q. Association between FOXE1 and non-syndromic orofacial clefts in a northeastern Chinese population. Br J Oral Maxillofac Surg 2015; 53: 705-710.
- [32] Lammer EJ, Mohammed N, Iovannisci DM, Ma C, Lidral AC and Shaw GM. Genetic variation of FOXE1 and risk for orofacial clefts in a California population. Am J Med Genet Part A 2016; 170A: 2770-2776.
- [33] Duan SJ, Zhang BH, Shi B, Shi YJ, He S, Jiang SY, Zeng N and Jia ZL. Thyroid cancer causal gene *FOXE1* involved in orofacial clefts in Western Han Chinese. Int J Clin Exp Med 2017; 10: 5398-5405.
- [34] Venza M, Visalli M, Venza I, Torino C, Tripodo B, Melita R and Teti D. Altered binding of MYF-5 to *FOXE1* promoter in non-syndromic and CHARGE-associated cleft palate. J Oral Pathol Med 2009; 38: 18-23.
- [35] Yin X, Zhang H, Zhu Z, Wang H, Du Y, Li S, Zhang Z, Fan W and Pan Y. FOXE1 polymorphisms and non-syndromic orofacial cleft susceptibility in a Chinese Han population. Oral Diseases 2016; 22: 274-279.
- [36] Uslu VV, Petretich M, Ruf S, Langenfeld K, Fonseca NA, Marioni JC and Spitz F. Long-range enhancers regulating Myc expression are required for normal facial morphogenesis. Nat Genet 2014; 46: 753-758.
- [37] Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, Liao H, Stephens RM, Harris TJ, Munroe DJ and Wu X. Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 2010; 107: 3001-3005.
- [38] Duan SJ, Shi B, Shi JY, Feng F and Jia ZL. Further evidence of GWAS signals in non-syndromic orofacial clefts from Western Han Chinese. J Interdiscipl Med Dent Sci 2016; 4: 1.